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Abstract
Ligand-targeted liposomes have the potential to increase the therapeutic efficacy of antineoplastic agents. Recently, a
combinatorial approach to the preparation of ligand-targeted liposomes has been developed, termed the post-insertion
technique, which will facilitate the production of targeted liposomes. In this paper, Stealth immunoliposomes (SIL) coupled
to anti-CD19 made by either a conventional coupling technique (SIL[anti-CD19]), or by the post-insertion technique
(PIL[anti-CD19], were compared with respect to their in vitro binding and cytotoxicity and their ability to improve in vivo
survival in tumor-bearing mice. The in vitro binding and uptake of PIL[anti-CD19] by CD19-expressing, B-cell lymphoma
(Namalwa) cells was similar to that of SIL[anti-CD19] and both were significantly higher than binding of non-targeted
liposomes (SL). In addition, no significant differences were found between the respective in vitro cytotoxicities
of doxorubicin-loaded PIL[anti-CD19] or SIL[anti-CD19], or in their in vivo therapeutic efficacy in a murine model
of human B-lymphoma. Overall, the results demonstrate that the post-insertion technique is a simple, flexible and
effective means for preparing targeted liposomal drugs for clinical applications. ß 2001 Elsevier Science B.V. All rights
reserved.
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Abbreviations: HSPC, hydrogenated soy phosphatidylcholine; mPEG-DSPE, polyethylene glycol (Mr 2000) covalently linked via a
carbamate bond to distearoylphosphatidylethanolamine; CHOL, cholesterol ; [3H]CHE, cholesterol-[1,2-3H-(N)]hexadecyl ether; NAM,
N-acetylmethionine; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; HEPES, 4-(2-hydroxyethyl)-1-piperazine eth-
anesulfonic acid; TI, tyraminylinulin; Mal-PEG-DSPE, maleimide-derivatized mPEG-DSPE; Hz-PEG-DSPE, hydrazide-derivatized
mPEG-DSPE; SL, Stealth liposomes composed of HSPC:CHOL:mPEG-DSPE; SIL, preformed SL containing coupling lipids that
were converted into Stealth immunoliposomes by coupling antibodies directly to the PEG terminus; IgG micelles, mPEG-DSPE micelles
with antibodies coupled to the PEG terminus of the micelles ; PIL, SL that were converted into immunoliposomes using the post-insertion
technology from IgG micelles; DXR, doxorubicin; DXR-SL, SL loaded with DXR; DXR-SIL[anti-CD19], SIL coupled to anti-CD19
and loaded with DXR; DXR-PIL[anti-CD19], PIL containing anti-CD19 transferred into preformed DXR-loaded liposomes
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1. Introduction
Ligand-targeted liposomes are being researched for
their ability to improve the selective toxicity of anti-
cancer drugs, with the ultimate aim of improving the
therapeutic e⁄cacy and quality of life for cancer pa-
tients. Ligand-targeted liposomal anticancer drugs
have been shown to have increased binding, im-
proved cytotoxicities, and in many cases improved
therapeutic e⁄cacy, compared to non-targeted lipo-
somes [1^10]. If ligand-targeted liposomes are to pro-
ceed to clinical trials, simple, £exible methods for
their preparation need to be developed. A novel
method to prepare ligand-targeted liposomes, termed
the post-insertion technique, has recently been devel-
oped [11]. This method is a logical progression from
the work of Uster et al. [12] and involves the cou-
pling of ligands to the terminus of polyethylene gly-
col (PEG)-lipid derivatives in a micellar phase fol-
lowed by the time- and temperature-dependent
transfer of the ligand-coupled PEG-lipids into the
bilayers of pre-formed, drug-loaded liposomes during
a simple incubation step. This is appealing from a
manufacturing point of view because a wide variety
of ligands (including antibodies, antibody fragments,
peptides, carbohydrates, etc.) could be easily inserted
into liposomes containing any one of a wide variety
of drugs (including those that have already been ap-
proved for clinical use, e.g. Caelyx0 or Myocet0). It
is also appealing from a clinical standpoint because
post-insertion liposomes can be tailor-made to ac-
commodate both the drug sensitivity of the particu-
lar malignancy and its receptor or antigen expres-
sion, leading to improvements in therapeutic e¡ect.
Ishida et al. have previously shown that it is pos-
sible to prepare post-insertion immunoliposomes
(PIL) that satisfy many of the established criteria
for ‘ideal immunoliposomes’ [11,13]. The technique
is simple, an appropriate level of stable ligand incor-
poration can be achieved, and the method does not
compromise the drug-loading or drug release charac-
teristics of doxorubicin-loaded liposomes [11]. In this
paper the in vitro binding and cytotoxicity of immu-
noliposomes (PIL or Stealth immunoliposomes
(SIL)) targeted with anti-CD19 monoclonal antibody
were evaluated using a CD19 B-lymphoma cell line
(Namalwa). The in vivo survival bene¢t of PIL was
also evaluated and compared to that of SIL in a
murine model of human B-cell lymphoma.
2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC),
methoxypoly(ethylene glycol) (MW 2000) covalently
linked to distearoylphosphatidylethanolamine
(mPEG2000-DSPE) [14], hydrazide-derivatized
PEG2000-DSPE (Hz-PEG-DSPE) [15], and doxorubi-
cin (DXR) were generous gifts from Alza Pharma-
ceuticals (Mountain View, CA). Maleimide-derivat-
ized PEG2000-DSPE (Mal-PEG-DSPE) was custom
synthesized by Shearwater Polymers (Huntsville,
AL). Cholesterol (CHOL) was purchased from
Avanti Polar Lipids (Alabaster, AL). Cholesterol-
[1,2-3H-(N)]-hexadecyl ether ([3H]CHE), 1.48^2.22
TBq/mmol, and Na125I (185 mBq) were purchased
from Mandel Scienti¢c (Mississauga, ON). [Carba-
moyl-14C]mPEG2000-DSPE (17.75 mCi/g) was custom
synthesized by Chemsyn Science Laboratories (Le-
nexa, KS). Nuclepore polycarbonate membranes
(pore sizes: 0.2, 0.1, and 0.08 Wm) were purchased
from Northern Lipids (Vancouver, BC). Sephadex
G-25 and G-50, Sepharose CL-4B, aqueous counting
scintillant (ASC), and Hi-Trap protein G columns
were purchased from Amersham Pharmacia Biotech
(Baie d’Urfe¤, QC). N-Acetylmethionine (NAM), so-
dium periodate, 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT), 2-iminothiolane
(Traut’s reagent), and sheep IgG (reagent grade)
were purchased from Sigma (St. Louis, MO). 4-(2-
Hydroxyethyl)-1-piperazine ethanesulfonic acid
(HEPES) was purchased from BDH (Toronto,
ON). Tyraminylinulin (TI) synthesis and preparation
of [125I]TI have been previously described [16]. RPMI
1640 medium (without phenol red), penicillin-strep-
tomycin, and fetal bovine serum (FBS) were pur-
chased from Life Technologies (Burlington, ON).
All other chemicals were of analytical grade purity.
2.2. Cell lines and mice
The human Burkitt’s lymphoma cell line, Namal-
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wa (ATCC CRL 1432) (Rockville, MD) was grown
in suspension at 37‡C in 5% CO2 and 90% humidity
in full RPMI supplemented with 10% FBS, 50 units/
ml penicillin G, and 50 Wg/ml streptomycin sulfate.
For experimental purposes, only cells in the exponen-
tial phase were used and CD19 expression was con-
¢rmed by £ow cytometry [7].
Female, 6^8 week old Balb/C cr Alt BM mice were
obtained from Health Sciences Lab Animal Services
(University of Alberta, Edmonton, AB) and kept in
standard housing. Female, 6^8 week old C.B.-17/
ICR-Tac-SCID mice were purchased from Taconic
Farms (German Town, NY) and housed under virus-
and antigen-free conditions. They were fed autoclav-
able rodent chow and received trimethoprim-sulfa-
methoxazole in their drinking water. Both strains
of mice were used for experiments after a minimum
acclimation period of 1 week, when they were 7^12
weeks old. All experiments were approved by
the Health Sciences Lab Animal Services Animal
Policy and Welfare Committee of the University of
Alberta.
2.3. Preparation of anti-CD19 antibody
Murine monoclonal anti-CD19 antibody (IgG2a)
was produced in BALB/c cr Alt BM mice using the
FMC63 murine hybridoma obtained from Dr. H.
Zola, Children’s Health Research Institute, Adelaide,
Australia [17]. The antibody was puri¢ed from as-
cites £uid by centrifugation followed by ¢ltration of
the supernatant and puri¢cation on a protein G af-
¢nity column according to the manufacturer’s in-
structions. A non-speci¢c isotype-matched antibody
that does not bind to Namalwa cell epitopes was
obtained from the PK136 hybridoma (ATCC HB-
191). Iodination of anti-CD19 was as previously de-
scribed [7].
2.4. Preparation of liposomes
Non-targeted sterically stabilized liposomes (SL)
were composed of HSPC:CHOL:mPEG2000-DSPE
at a 2:1:0.1 molar ratio. Targeted formulations
were composed of 4 mol% mPEG2000-DSPE and
1 mol% of coupling lipid (Mal-PEG2000-DSPE [18]
or Hz-PEG2000-DSPE [7]). Formulations were made
with either the anti-CD19 monoclonal antibody
(mAb) or with an isotype-matched control antibody
that did not bind to Namalwa cells. In some cases a
non-metabolizable, non-exchangeable radioactive
tracer, [3H]CHE (30^60 kBq), was added to the lipid
mix. Extrusion of the liposomes to homogeneous size
was as previously described [7]. Brie£y, dried lipid
¢lms were hydrated at a concentration of 20^30
mM phospholipid (PL) and sequentially extruded
(Lipex Biomembranes Extruder, Vancouver, BC)
through a series of polycarbonate membranes with
pore sizes ranging from 0.2 Wm down to 0.08 Wm.
The ¢nal liposome size was 100 þ 10 nm with a poly-
dispersity ranging from 0.08 to 0.12. Liposomes for
binding assays were hydrated in HEPES bu¡er, pH
7.4. When doxorubicin-loaded liposomes were re-
quired for in vitro cytotoxicity and in vivo therapeu-
tic studies, the lipid was hydrated in 250 mM ammo-
nium sulfate at pH 5.5.
For doxorubicin loading the liposome external
bu¡er was exchanged for 100 mM Na acetate, 70
mM NaCl at pH 5.5 by chromatography on a CL-
4B column and DXR was loaded by the ammonium
sulfate gradient method [19] at a ratio of 0.2:1,
DXR:HSPC (w/w) as previously described [20].
The DXR concentration was determined by spectro-
photometry (V= 450 nm) from the absorbance of the
loaded liposomes dissolved in methanol and the
phospholipid concentration was determined by the
Bartlett colorimetric assay [21]. The ¢nal loading ra-
tio was approx. 0.26 Wmol DXR/Wmol PL, which
translates into approx. 99% loading e⁄ciency.
2.5. Preparation of micelles
Lipid mixtures, composed of Mal-PEG2000-DSPE
and mPEG2000-DSPE at a 4:1 molar ratio, were
dried from chloroform for 1 h using a rotor-evapo-
rator, then overnight under high vacuum. The lipids
were hydrated immediately before coupling at a con-
centration of 10 mM in deoxygenated 25 mM
HEPES, pH 7.4, by heating in a 65‡C water bath
with occasional gentle vortexing.
2.6. Antibody coupling to liposomes or micelles
Antibodies were usually coupled to the PEG ter-
mini of liposomes or micelles using the Mal-PEG
coupling method [18]. The method was modi¢ed
BBAMEM 78124 9-7-01
D.L. Iden, T.M. Allen / Biochimica et Biophysica Acta 1513 (2001) 207^216 209
for the coupling of whole antibody as described by
Lopes de Menezes et al. [22]. For coupling to mi-
celles, the antibody was thiolated at an antibody
concentration of 12 mg/ml and a ratio of
Traut’s:IgG of 10:1 (mol/mol). The thiolated anti-
body was then promptly added to the liposomes or
micelles at a speci¢ed molar ratio of IgG:PEG2000-
DSPE, taking care to avoid exposure to oxygen. For
coupling to liposomes, approx. 45 Wg Ab was added
per Wmol PL, which corresponds to a molar ratio of
1:3333 (Ab:liposome PL). Micelles were coupled at a
molar ratio of 10:1, Mal-PEG2000-DSPE:IgG.
2.7. Transfer of antibodies from micelles to liposomes
Following coupling, the IgG micelles were ¢ltered
through a 0.22 Wm ¢lter to remove any micelle ag-
gregates that might have resulted from cross-linking.
Micelles were then incubated with pre-formed lipo-
somes containing 4 mol% PEG at a molar ratio of
0.05:1 (micelle PL:liposomal HSPC) for 1 h at 60‡C.
Following transfer, the liposome^micelle mixture was
cooled and chromatographed over a Sepharose CL-
4B column, equilibrated with pH 7.4 HEPES bu¡er,
to separate the liposomes from non-transferred mi-
cellar PL and free antibody. The antibody incorpo-
ration ranged from 25 to 40 Wg Ab/Wmol liposome
PL.
2.8. In vitro binding and uptake of immunoliposomes
Binding experiments were performed as previously
described [7]. Liposomes of di¡erent formulations,
including non-targeted Stealth liposomes (SL) and
anti-CD19-targeted liposomes made by conventional
techniques (SIL[anti-CD19]) or post-insertion tech-
niques (PIL[anti-CD19]), were prepared with 55.5
kBq of [3H]CHE per Wmol PL. Namalwa cells
(1U106 cells/well) were plated in a volume of 0.2
or 0.3 ml. In competition experiments, excess free
anti-CD19 (3-fold at the highest PL concentration
and 97-fold at the lowest) was added to the wells
20 min before the addition of SIL[anti-CD19] or PI-
L[anti-CD19]. Control immunoliposomes were made
using an isotype-matched control antibody substi-
tuted for the anti-CD19. The cells were incubated
for 1 h at 37‡C and the [3H]CHE counts associated
with the cells were determined after washing three
times with phosphate-bu¡ered saline. These data
were transformed into pmol PL uptake per 106 cells
using the speci¢c activity. Three replicates of binding
data were used to generate a binding curve and the
Bmax and Kd values were determined by non-linear
regression using GraphPad Prism software (San Die-
go, CA).
2.9. Cytotoxicity experiments
The cytotoxicities of free DXR, or doxorubicin
loaded into non-targeted liposomes (DXR-SL), or
targeted liposomes (DXR-SIL[anti-CD19] or DXR-
PIL[anti-CD19]) was determined for Namalwa cells
using the MTT assay [23]. The procedure has been
previously described [7]. 5U104 Namalwa cells were
plated in 96-well, round bottom plates in a volume of
0.1 ml. The cells were exposed to drug for either 1 or
24 h.
2.10. Pharmacokinetics
For pharmacokinetics (PK) determinations, lipo-
somes were loaded with 125I-TI and experiments
were performed as previously described [7]. For the
targeted formulations, either sheep IgG or anti-CD19
antibodies were coupled to the liposomes. The stud-
ies were carried out in either naive (no tumor) Balb/
C cr Alt BM mice or in SCID mice inoculated i.v.
with 5U106 cells Namalwa cells in 0.2 ml at 24 h
prior to initiation of the PK studies. Pharmacoki-
netic parameters were calculated using a polyexpo-
nential curve stripping and least squares parameter
estimation program, PKAnalyst Software (Micro-
math, Salt Lake City, UT).
2.11. Therapeutic e⁄cacy
The therapeutic e⁄cacies were compared in SCID
mice inoculated i.v. with 5U106 cells Namalwa cells,
as previously described [7]. Treatments were given at
24 h post inoculation and consisted of saline con-
trols, free DXR, DXR-SL, DXR-SIL[anti-CD19] or
DXR-PIL[anti-CD19]. The mice were dosed at 2.5
mg DXR/kg according to the mean weight of each
treatment group. The mice were monitored daily and
euthanized at the onset of hind leg paralysis (HLP),
or upon reaching a moribund state.
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2.11. Statistical analysis
Comparisons of binding, cytotoxicity, pharmaco-
kinetics and therapeutic e⁄cacies were done using a
one-way analysis of variance (ANOVA) with Graph-
Pad Instat Software, version 3.0 (San Diego, CA).
The Tukey post-test was used to compare the di¡er-
ent treatment means and P-values less than 0.05 were
considered signi¢cant. The Kd and Bmax for SIL[anti-
CD19] and PIL[anti-CD19] were statistically com-
pared using an unpaired t-test and GraphPad Prism
software.
3. Results
3.1. In vitro binding and uptake
The radiolabeled counts associated with the cells
re£ect a combination of binding to cell surface CD19
epitopes and receptor-mediated internalization of the
liposomes. In vitro binding and uptake of SL, SI-
L[anti-CD19] or PIL[anti-CD19] by Namalwa cells
is shown in Fig. 1. As expected, the non-speci¢c ab-
sorption of SL to Namalwa cells increased linearly
with increasing concentrations of PL (Fig. 1A). The
association of SIL coupled to a non-speci¢c, isotype-
matched antibody was not di¡erent from that ob-
served for SL (Fig. 1). For the targeted formulations
at a PL concentration of 400 nmol/ml, the total bind-
ing and uptake for SIL[anti-CD19] or PIL[anti-
CD19] were 6.0-fold or 5.0-fold greater than SL, re-
spectively (P6 0.001) (Fig. 1A). The speci¢c binding
and uptake of PIL or SIL saturated above PL con-
centrations of 400 nmol/ml (Fig. 1B). No signi¢cant
di¡erences were observed between SIL and PIL. In
Table 1
Cytotoxicity of non-targeted and anti-CD19-targeted formulations of DXR against CD19 Namalwa cells
Formulation IC50 (WM DXR), 1 h (n = replicates) IC50 (WM DXR), 24 h (n = replicates)
Free DXR 0.6 þ 0.3 (n = 3) 0.3 þ 0.1 (n = 3)
DXR-SL 142.0 þ 27 (n = 3) 5.1 þ 1.3 (n = 4)
DXR-SIL[anti-CD19] 35 þ 25 (n = 3) 2.8 þ 0.7 (n = 4)
DXR-PIL[anti-CD19] 31 þ 8.9 (n = 4) 2.8 þ 0.5 (n = 3)
Namalwa cells (5U105) were incubated with various liposome formulations (six wells each) for 1 or 24 h at 37‡C in an atmosphere of
5% CO2 and 90% humidity. The liposomes were composed of HSPC:CHOL:mPEG2000-DSPE (2:1:0.1, mol/mol) and targeted formu-
lations were coupled to 25^40 Wg anti-CD19/Wmol PL using the Mal-PEG coupling method. Each plate was incubated for a total of
48 h, after which an MTT assay was performed. The data are expressed as mean IC50 in WM þ S.D. for three or four separate repli-
cates (n) of the MTT assay.
Fig. 1. Comparison of the binding and uptake of non-targeted
liposomes with anti-CD19-targeted liposomes. Liposomes were
composed of HSPC:CHOL:mPEG2000-DSPE, at a molar ratio
of 2:1:0.1 (100 þ 10 nm in diameter) and labeled with [3H]CHE.
Targeted formulations contained 25^40 Wg anti-CD19/Wmol PL.
Increasing concentrations of SL (b), SIL[anti-CD19] (F) or PI-
L[anti-CD19] (R) (n = 3) were incubated with 1U106 Namalwa
cells for 1 h at 37‡C. Isotype-matched control preparations of
SIL[IgG2a] (E, solid line) or PIL[IgG2a] (O, solid line) were
also examined. In competition experiments 3^97-fold excess free
anti-CD19 was incubated with the cells at 20 min before the
addition of SIL[anti-CD19] (E, dashed line) or PIL[anti-CD19]
(O, dashed line) (n = 6). (A) Total cell-associated PL; (B) spe-
ci¢c binding and uptake for SIL[anti-CD19] or PIL[anti-CD19].
Data are expressed as pmol PL/106 cells þ S.D.
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competition experiments the speci¢c binding of both
SIL[anti-CD19] and PIL[anti-CD19] was inhibited
and binding and uptake levels became similar to
those of SL (Fig. 1A).
The number of binding sites (Bmax) and the Kd
( þ S.E.) were determined for the two targeted formu-
lations. The Bmax was found to be 604 þ 71 pmol/
1 000 000 cells for SIL[anti-CD19] and 568 þ 64
pmol/1 000 000 cells for PIL[anti-CD19]. There was
no signi¢cant di¡erence between Bmax for each of
the two targeted formulations. Similarly, there was
no signi¢cant di¡erence between the Kd for SIL[anti-
CD19] of 83 þ 48 WM and that of PIL[anti-CD19] of
79 þ 44 WM.
The number of liposomes per Wmol PL was calcu-
lated from the literature values for bilayer thickness
and the molecular areas for HSPC, CHOL, and
PEG-DSPE. Assuming that the liposomes were
spherical, 100 nm in diameter, and contained unila-
mellar bilayers with monodisperse PL, the number of
liposomes per Wmol PL is estimated at 7.7U1012.
From this information the number of antibodies
for liposomes containing 25^40 Wg anti-CD19/Wmol
PL was calculated to range between 13 and 21 anti-
bodies per liposome. Using these calculations, the
Bmax for SIL[anti-CD19] and PIL[anti-CD19] trans-
late into approx. 4654 and 4372 liposome binding
sites per cell, respectively.
Fig. 2. Blood clearance of targeted versus non-targeted lipo-
somes in mice. Mice (Balb/C cr Alt BM) were injected i.v. via
the tail vein with a single bolus dose of 0.5 Wmol liposome PL.
Liposomes were composed of HSPC:CHOL:mPEG2000-DSPE
(2:1:0.1, mol/mol, 100 þ 10 nm) and loaded with the aqueous
space marker 125I-TI. Formulations included SL (b), SIL[anti-
CD19] (F), and PIL[anti-CD19] (R). Targeted formulations
were coupled to 25^40 Wg Ab/Wmol PL. Data are expressed as
the % of cpm in blood of counts remaining in the body at each
time point (mean þ S.D., n = 3).
Fig. 3. Clearance of liposomes as a function of antibody, cou-
pling method or presence of tumor cells. Mice were injected i.v.
via the tail vein with a single bolus dose of 0.5 Wmol liposomal
PL. Liposomes were composed of HSPC:CHOL:PEG2000-DSPE
(2:1:0.1, mol/mol, diameter 100 þ 10 nm) and loaded with the
aqueous space marker 125I-TI. Targeted formulations were
coupled to 25^40 Wg Ab/Wmol PL using the Mal-PEG method
unless otherwise indicated. (A) Clearance in naive (no tumor)
BALB/c cr Alt BM mice as a function of the targeting Ab and
coupling method. b, SL; R, SIL[anti-CD19]; 8, Hz-PEG-SI-
L[anti-CD19]; F, PIL[anti-CD19]; O, SIL[Sheep IgG]; E, PIL[-
sheep IgG]. (B) Clearance of SL or anti-CD19 immunolipo-
somes in naive BALB/c cr Alt BM mice (closed symbols) vs.
SCID mice inoculated with 5U106 Namalwa cells 24 h prior to
liposomes (open symbols). b,a, SL; R,O, SIL[anti-CD19];
F,E, PIL[anti-CD19]. Data are expressed as the % cpm in
blood of counts remaining in the body at each time point
(mean þ S.D., n = 3).
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3.2. Cytotoxicity
The average in vitro IC50 values for free DXR,
DXR-SL, DXR-SIL[anti-CD19] or DXR-PIL[anti-
CD19] for several cytotoxicity assays are shown in
Table 1. Free doxorubicin was signi¢cantly more cy-
totoxic than DXR-SL, DXR-SIL[anti-CD19] or
DXR-PIL[anti-CD19] for the 1 h incubation
(P6 0.001) and the 24 h incubation (P6 0.05 to
P6 0.001). Targeted formulations were signi¢cantly
more cytotoxic than non-targeted formulations
(P6 0.001) but not signi¢cantly di¡erent from each
other (Ps 0.05).
3.3. Pharmacokinetics
The clearance pro¢les for 125I-TI-loaded SL, SI-
L[anti-CD19] or PIL[anti-CD19] in BALB/c mice
are shown in Fig. 2. Both of the targeted formula-
tions were cleared signi¢cantly more rapidly than SL.
The clearance pro¢les of the targeted formulations
were characterized by an early rapid phase of clear-
ance. Although PIL appeared to be removed more
rapidly than SIL, statistical comparison of the two
suggested that the di¡erence barely reached signi¢-
cance (P6 0.05).
As the source of antibody, as well as the coupling
method might a¡ect clearance, a comparison was
made of the clearance rates for immunoliposomes
for di¡erent antibodies and coupling methods and
in tumor-bearing versus non-tumor-bearing mice
(Fig. 3). The clearance kinetics for SIL or PIL
coupled to sheep IgG were not di¡erent from the
clearance kinetics of SL (Fig. 3A). Liposomes
coupled to anti-CD19 by the Mal-PEG method
were cleared more rapidly than liposomes coupled
to sheep IgG by the same method and PIL[anti-
CD19] and were cleared more rapidly than SIL[an-
ti-CD19], although this was barely statistically signif-
icant. Interestingly, SIL[anti-CD19] coupled by the
Mal-PEG method were cleared more rapidly than
similar liposomes prepared by a coupling method
that results in a hydrazone bond between the Fc
region of the antibody and the PEG [7]. The terminal
half-lives (t1=2L) for SL, SIL[sheep IgG], PIL[sheep
IgG], SIL[anti-CD19] or PIL[anti-CD19] were 21.8,
15.5, 17.7, 16.4, and 17.4 h, respectively (data not
shown). In all cases the volume of distribution, VD,
closely approximated the blood volume (data not
shown).
Since the clearance of anti-CD19-targeted lipo-
somes is expected to be altered in tumor-bearing
mice, the clearance of PIL[anti-CD19] or SIL[anti-
CD19] was evaluated in SCID mice injected i.v.
with Namalwa cells, which is the same animal model
used to evaluate the therapeutic e⁄cacy. As ex-
pected, the clearance of the targeted liposomes, but
not the non-targeted liposomes, was more rapid in
tumor-bearing SCID mice than in conventional Balb/
c mice (Fig. 3B). Two hours post injection only 25^
35% of the administered dose remained in blood for
PIL[anti-CD19] or SIL[anti-CD19] in tumor-bearing
mice.
3.4. In vivo therapeutics
Table 2 shows the mean survival times (MST) and
% increased life spans (ILS) for mice treated with
saline, free DXR, DXR-SL, DXR-SIL[anti-CD19]
or PIL[anti-CD19]. There were no signi¢cant di¡er-
Table 2
Therapeutic e⁄cacy of non-targeted and targeted formulations of DXR in SCID mice implanted with human B-lymphoma cells
Formulation MST þ S.D. (days) ILS (%)
Saline control (n = 6) 28.2 þ 2.1 ^
Free DXR (n = 5) 31.0 þ 3.7 9.9
DXR-SL (n = 5) 29.8 þ 2.6 5.7
DXR-SIL[anti-CD19] (n = 7) 38.4 þ 4.2 36.2
DXR-PIL[anti-CD19] (n = 5) 36.6 þ 3.2 29.8
SCID mice received i.v. Namalwa cells (5U106 cells in 0.2 ml) 24 h before a single treatment with 2.5 mg/kg DXR. Liposomes were
composed of HSPC:CHOL:mPEG-DSPE (2:1:0.1, mol/mol, 100 þ 10 nm) with or without 25 Wg anti-CD19/Wmol liposome PL,
coupled to the PEG terminus by the Mal-PEG method. Doxorubicin was loaded into liposomes by the ammonium sulfate gradient
method at 0.2 mg DXR/mg PL. MST denotes mean survival time and ILS denotes increased life span (n = 5).
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ences in the MST for saline, free DXR or DXR-SL.
However, both targeted formulations showed signi¢-
cantly increased MST compared to the other formu-
lations (P6 0.05 to Ps 0.001). No signi¢cant di¡er-
ences were observed between DXR-PIL[anti-CD19]
and SIL[anti-CD19].
4. Discussion
In this paper the in vitro and in vivo binding,
cytotoxicity and therapeutic e¡ects of anti-CD19 im-
munoliposomes made by the post-insertion technique
were compared to those of immunoliposomes made
by a conventional coupling technique using a human
B-lymphoma model. In terms of the assay results,
there was little to choose between the two methods
for preparing immunoliposomes. However, in terms
of their ease and speed of preparation and their £ex-
ibility, PIL would be the clear favorite for use in
manufacturing immunoliposomes for clinical appli-
cations.
The results from the binding and competition ex-
periments support a conclusion that, in the case of
both SIL[anti-CD19] and PIL[anti-CD19], the anti-
body mediated a speci¢c targeting e¡ect. In addition,
these experiments and previous experiments in our
laboratory using non-speci¢c isotype control anti-
bodies have demonstrated that this e¡ect is speci¢c
to anti-CD19 [7,24]. Further, the Kd and Bmax for
both preparations were similar.
Interestingly, the estimated number of binding
sites for the anti-CD19 immunoliposomes was ap-
prox. 7-fold lower than that previously reported [7]
and was also lower than the number of sites reported
for free anti-CD19 mAb (HD37) [25]. The reason for
this disparity may be related to di¡erences in the
coupling method between these and previous results.
In the previous study, the hydrazide coupling method
was employed [7]. This method, which couples anti-
bodies to the PEG terminus through their Fc region,
results in the attachment of antibodies in a consistent
orientation that leaves the antigen-binding region ex-
posed and able to interact with the target. The cou-
pling method employed in this study (Mal-PEG) re-
sults in random thiolation of the antibody and
therefore random orientation of the antibody on
the liposome. This may result in screening or block-
ing of the binding region of the antibody and an
apparent reduction in the number of binding sites.
In addition, the introduction of sulfhydryl groups to
amino acids within the antigen-binding region of the
antibody by Traut’s reagent could interfere with
binding. Indeed, antibody activated with Traut’s re-
agent has been shown to bind less e¡ectively to Na-
malwa cells than non-treated antibody (Allen labo-
ratory, unpublished results). Further, while small
changes in the antigen-binding region may not pre-
vent binding of the anti-CD19 antibody to the CD19
epitope, it is possible that receptor activation could
be blocked, leading to decreased levels of receptor-
mediated endocytosis and decreased receptor recy-
cling (recall that the binding results are a sum of
both binding and uptake). The Mal-PEG coupling
method was originally described for the coupling of
antibody fragments to liposomes [18]. Since FabP
fragments can be easily coupled to lipids via natu-
rally occurring inter-chain sulfhydryl groups, there is
no need for thiolation of the antibody. Preliminary
results from our laboratory suggest that SIL[anti-
CD19] made with FabP fragments rather than whole
antibody have improved binding and uptake by Na-
malwa cells (manuscript in preparation). This further
suggests that the antibody binding may be compro-
mised by thiolation.
Overall, the cytotoxicity results were in agreement
with the previous ¢ndings by Lopes de Menezes et al.
[7] and no di¡erences between PIL[anti-CD19] and
SIL[anti-CD19] were observed. Since there was no
signi¢cant di¡erence in the Bmax and Kd for either
of the two targeted formulations, it is likely that
the equivalent cytotoxicity results by a similar mech-
anism of drug delivery to the target cells, probably
by receptor-mediated endocytosis of intact lipo-
somes. The targeted formulations were expected to
have a cytotoxic advantage due to receptor-mediated
endocytosis of the drug-loaded liposomes. Intracellu-
lar delivery of drug-loaded liposomes is thought to
increase drug exposure, provided that the drug is
released from the endosome^lysosome compartment
[22]. Conversely, the cytotoxicity of DXR-SL is de-
pendent on the release of DXR from the liposomes,
which occurs slowly. Hence the very low cytotoxicity
of DXR-SL for short incubation times was not sur-
prising. At longer time points, release of drug from
DXR-SL would be higher and the di¡erences be-
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tween non-targeted and targeted formulations should
decrease, as we observed.
Because the post-insertion technique involves ex-
posing the antibody to elevated temperature (60‡C)
for 1 h, the potential exists for detrimental e¡ects on
the antibody that could reduce its binding a⁄nity
and/or avidity for its target antigen. Since no signi¢-
cant di¡erences were observed between PIL and SIL
in binding, cytotoxicity or therapeutic bene¢t, the
antibody appears to be stable at this temperature
over this incubation time.
Both targeted formulations were cleared more rap-
idly than the non-targeted formulations in naive, im-
mune-competent mice, likely due to the binding of
liposomes to CD19-expressing normal B-cells in the
Balb/c mice. This explains the increased rate of clear-
ance of anti-CD19 immunoliposomes compared to
sheep IgG immunoliposomes. It also suggests that
the behavior of immunoliposomes in vivo may be
subject to antibody- or model-speci¢c e¡ects and
the results reported in this study cannot necessarily
be extended to other antibodies or other coupling
methods. For example, in this study the rate of clear-
ance of SIL[anti-CD19] coupled by the Mal-PEG
method was faster than previously reported for SI-
L[anti-CD19] made by the Hz-PEG coupling method
[7]. In our current study, a direct comparison of SI-
L[anti-CD19] prepared by the Hz-PEG vs. Mal-PEG
methods showed an increased rate of clearance for
the latter, despite equivalent antibody densities. Since
the hydrazide coupling method is site-directed to the
Fc region of the antibody, clearance of the immuno-
liposomes by Fc receptor-mediated mechanisms will
be substantially reduced relative to the Mal-PEG
method where the Fc region of the antibody may
be exposed on some proportion of the antibody pop-
ulation. Overall, this ¢nding suggests that the Mal-
PEG coupling method would be more bene¢cially
applied to FabP or scFv fragments that lack the Fc
portion of the antibody. Preliminary work in our
laboratory has shown that SIL[anti-CD19 FabP] pre-
pared using the Mal-PEG method are cleared much
less rapidly than SIL[anti-CD19] (whole antibody).
For example, at 24 h post injection 30% of SIL[an-
ti-CD19 FabP] remained in blood compared to only
3% of SIL[anti-CD19] (manuscript in preparation).
Although there was a tendency for PIL to be
cleared more rapidly than SIL, this was barely sig-
ni¢cant and could have been due to small variations
in the numbers of antibodies at the liposome surface
since the pharmacokinetics is sensitive to antibody
density. Although every attempt was make to match
the antibody densities in samples, it is impossible to
do this exactly. Although we have no evidence for
this as yet, there may also be di¡erences in the ori-
entation of the antibody during the coupling proce-
dure when coupling is done with micelles as opposed
to whole liposomes. This might result in changes in
the degree of exposure of the binding site region or
the Fc region of the antibody that might a¡ect the
pharmacokinetics.
It would be desirable if the clearance of the tar-
geted formulations were slower than reported here.
However, since binding and internalization in vitro
are rapid (within a few minutes), the circulation half-
lives of the immunoliposomes should be long enough
to allow in vivo binding and uptake leading to a
therapeutic e¡ect. Indeed, mice treated with SIL[an-
ti-CD19] and PIL[anti-CD19] had signi¢cantly in-
creased survival times compared to free drug or
non-targeted liposomes, and there was no signi¢cant
di¡erence between the two targeted formulations.
The therapeutic advantage of anti-CD19 immunoli-
posomes has been previously shown to be speci¢c to
anti-CD19 and to require the presence of DXR in
the liposomes [7]. In other words, the cytotoxic e¡ect
of anti-CD19 antibody is not primarily responsible
for the therapeutic e¡ect [7,26].
Given that the pharmacokinetics for SIL[anti-
CD19] and PIL[anti-CD19] prepared by the Mal-
PEG coupling method were less favorable than the
pharmacokinetics previously reported for SIL[anti-
CD19] prepared by the Hz-PEG method [7], it might
be expected that the therapeutic e⁄cacy would de-
crease. Using an identical model, Lopez de Menezes
et al. reported an ILS of 60% (versus an ILS of
36.2% in our study) for mice treated with a slightly
higher dose, 3 mg/kg DXR-SIL[anti-CD19] (versus
2.5 mg/kg in our study), at the same tumor cell bur-
den, route of injection and time of treatment post
inoculation [7]. The decrease in dose, the decreased
binding e⁄cacy due to random orientation of the
antibody, as well as the more rapid clearance kinetics
are likely responsible for the poorer response.
This study shows that the post-insertion approach
is amenable to the preparation of CD19-targeted im-
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munoliposomes, loaded with doxorubicin by the am-
monium sulfate method. However, for this approach
to be widely applicable to the manufacture and ad-
ministration of targeted liposomes, it is necessary to
demonstrate that the post-insertion approach is
widely applicable to the preparation of targeted lipo-
somes using other antibodies, antibody fragments,
peptides or other ligands as well as other drugs.
Nevertheless, it would appear that the post-insertion
approach to the formulation of immunoliposomes
has the necessary ease, speed and £exibility of pro-
duction and the therapeutic e⁄cacy that makes it
useful from the manufacturing perspective, as well
as the clinical perspective, for improving the selective
toxicity of anticancer or other drugs.
Note added in proof
A recent paper (M. Sugano, J.K. Egilmez, S.J.
Yokota, F.-A. Chen, J. Harding, S.K. Huang, R.B.
Bankert, Cancer Res. 60 (2000) 6942^6949) used the
post-insertion technique to insert FabP-antibody
fragments into preformed liposomal doxorubicin
and these were used, with good therapeutic e⁄cacy,
in a human lung tumor xenograft model in SCID
mice.
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